S2437 Budd-Chiari Syndrome Secondary to SARS-CoV-2 Infection

Rozenshteyn, Frederick; Shah, Michelle; Adeyemo, Oluwasayo; Smith, Michael S.

doi:10.14309/01.ajg.0000711796.23564.34

Cited by 4 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…12 In 3 reported cases, anticoagulation therapy was successful in resolving symptoms, with one case showing improvement within 1 month of diagnosis. 5,6,13 However, our patient experienced a complicated course, with multiple complications arising from increased portosystemic pressure despite being on anticoagulation. Owing to his high risk of hepatic encephalopathy, transjugular intrahepatic portosystemic shunt was not pursued.…”

Section: Discussionmentioning

confidence: 81%

Fulminant Presentation of Budd-Chiari Syndrome Secondary to COVID-19 Infection

Sanekommu,

Taj,

Kilada

et al. 2023

ACG Case Rep J

View full text Add to dashboard Cite

Budd-Chiari syndrome (BCS) is a rare condition characterized by the obstruction of hepatic venous outflow. It is estimated to affect 1 in 100,000 people worldwide. In cases of new BCS, inherited and acquired hypercoagulability states must be evaluated. Coronavirus disease 2019 (COVID-19) can induce a hypercoagulable state because of its extensive inflammatory response, and while it has been reported to cause portal vein thrombosis, it rarely causes BCS. This article presents a case of a 22-year-old man who developed fulminant symptoms and was subsequently diagnosed with BCS and portal vein thrombosis secondary to COVID-19 infection, after ruling out other inherited and acquired causes of BCS. In addition, a literature review is provided to understand the presentation and management of such patients. Although most patients improve with medical management, this article emphasizes the consideration of liver transplant for patients who do not improve.

show abstract

Section: Discussionmentioning

confidence: 81%

Fulminant Presentation of Budd-Chiari Syndrome Secondary to COVID-19 Infection

Sanekommu,

Taj,

Kilada

et al. 2023

ACG Case Rep J

View full text Add to dashboard Cite

show abstract

“…Overall, 641 articles were screened, 21 of which were selected according to the above mentioned criteria 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 . The included articles were all case reports (except for one case series [10] ), and contained description of 21 cases.…”

Section: Resultsmentioning

confidence: 99%

Acute splanchnic vein thrombosis in patients with COVID-19: A systematic review

Buso¹,

Becchetti²,

Berzigotti³

2021

Digestive and Liver Disease

View full text Add to dashboard Cite

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

show abstract

“…Se realizó una revisión en la literatura de casos publicados de estas dos entidades clínicas y se encontró que existen pocos reportes de casos publicados (10)(11)(12)(13)(14) , por lo que creemos que estos hallazgos son importantes debido a que describimos el diverso espectro de la patogénesis de la COVID-19 y la heterogeneidad en la presentación clínica, como fue en este caso de SBC subagudo.…”

Section: Reporte De Casounclassified

Síndrome de Budd-Chiari por COVID-19: una asociación poco frecuente

Velasco Castro,

Patarroyo,

Galan

et al. 2023

Rev. colomb. Gastroenterol.

View full text Add to dashboard Cite

Introducción: el coronavirus del síndrome respiratorio agudo grave de tipo 2 (SARS-CoV-2) es un virus que puede causar infecciones respiratorias y poner en riesgo la vida de los pacientes. Aunque afecta principalmente las vías respiratorias, se pueden presentar manifestaciones clínicas extrapulmonares como estados de hipercoagulabilidad, lo que causa patologías como enfermedad cerebrovascular e infarto agudo de miocardio, y en casos menos frecuentes, síndrome de Budd-Chiari. Caso clínico: se presenta el caso de una paciente que ingresó al servicio de urgencias por disnea de medianos esfuerzos, deterioro progresivo de la clase funcional y edema en extremidades inferiores asociado con tos, fiebre y adinamia. Refirió el antecedente de infección por enfermedad por coronavirus de 2019 (COVID-19) un mes antes y la tomografía de abdomen contrastada reveló síndrome de Budd-Chiari subagudo de la vena subhepática media asociada a trombosis del ventrículo derecho con prueba positiva para SARS-CoV-2. Conclusiones: El síndrome de Budd-Chiari es de origen multicausal, principalmente por estados de hipercoagulabilidad o presencia de neoplasias que ocasionan disrupción de la función del hígado o causan la ocupación de espacio sobre el drenaje venoso hepático; sin embargo, en el contexto de la pandemia de SARS CoV-2, aún se conoce muy poco la heterogeneidad de su patogénesis, como es la hipercoagulabilidad de la COVID-19 y el síndrome de Budd-Chiari, por lo que inferimos que están altamente relacionados.

show abstract

S2437 Budd-Chiari Syndrome Secondary to SARS-CoV-2 Infection

Cited by 4 publications

References 0 publications

Fulminant Presentation of Budd-Chiari Syndrome Secondary to COVID-19 Infection

Fulminant Presentation of Budd-Chiari Syndrome Secondary to COVID-19 Infection

Acute splanchnic vein thrombosis in patients with COVID-19: A systematic review

Síndrome de Budd-Chiari por COVID-19: una asociación poco frecuente

Contact Info

Product

Resources

About